GeoVax Q1 net loss narrows to $5.4M; BARDA award ended, COVID vaccine data due Q2 2025

GeoVax Labs, Inc.

Net loss $5.4M (vs $5.9M Q1 2024); revenue $1.6M from BARDA contract (none prior year).
Cash $7.4M at Mar 31, 2025, up from $5.5M at Dec 31, 2024.
BARDA Project NextGen award terminated unexpectedly; GEO-CM04S1 COVID vaccine continues.
Healthy adult booster data for GEO-CM04S1 expected Q2 2025; GEO-MVA trial starts H2 2025.
Gedeptin advancing to Phase 2 for recurrent head/neck cancer with checkpoint inhibitor.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.